Summary
Written to contribute to the European Commission's Communication on evaluation of the EU Action Plan, this paper highlights evidence of legislative activity related to new synthetic drugs as an indicator of Member States’ commitment to the issue. It also examines to what extent legal activity may be attributed to the EU action plan on drugs. Among others, the paper describes the wide variety of procedures that individual Member States are obliged to follow in order to control a new substance. These vary greatly between countries with the result that some simply cannot react as fast as others. This, in turn, may weaken the rationale of a fast, pan-European response to new synthetic drugs, and the effectiveness of the 1997 Joint action.
Download as PDF
New-Synthetic-Drugs-report.pdf
PDF files are made available as a convenience. In cases where the EMCDDA is not the originator of the document, please be aware that any PDFs available on this page may not be authoritative or there may be more recent versions available. While we make every effort to ensure that these files are definitive, before using or citing them, we recommend that you consult the publisher's website or contact the author(s) to check for more recent versions.
- Open access
- English